2022 - A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2- NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY (ZEST)
Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Hiroshi Tada, Shinji Ozaki, et al. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer. Breast Cancer Research and Treatment. 2023
KAZUO MATSUURA, AKIHIKO OSAKI, YUKI ICHINOSE, AKIHIRO FUJIMOTO, AYAKA SAKAKIBARA, ASAMI NUKUI, HIDEKI YOKOGAWA, HIROKO SHIMADA, AYA ASANO, MASAHIRO OHARA, et al. Clinicopathological prognostic characteristics and long-term outcomes of patients with breast cancer and collagen disorder in comparison to those without collagen disorder. ONCOLOGY LETTERS. 2023. 26. 495
Masahiro Takada, Shigeru Imoto, Takanori Ishida, Yoshinori Ito, Hiroji Iwata, Norikazu Masuda, Hirofumi Mukai, Shigehira Saji, Takafumi Ikeda, Hironori Haga, et al. A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer. Breast Cancer Research and Treatment. 2023
Kiichiro Ninomiya, Daisuke Inoue, Ken Sugimoto, Chie Tanaka, Keiko Murofushi, Toru Okuyama, Shigeaki Watanuki, Chiyo K. Imamura, Daisuke Sakai, Naomi Sakurai, et al. Significance of the comprehensive geriatric assessment in the administration of chemotherapy to older adults with cancer: Recommendations by the Japanese Geriatric Oncology Guideline Committee. Journal of Geriatric Oncology. 2023
Hitomi Sakai, Junji Tsurutani, Yukinori Ozaki, Hiroshi Ishiguro, Kazuki Nozawa, Kenichi Watanabe, Shigeto Maeda, Takamichi Yokoe, Chiyo K Imamura, Koji Matsumoto, et al. Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B). BMJ Open. 2023
Ayane Yamaguchi, Kosuke Kawaguchi, Hiroshi Ishiguro, Tatsuki R. Kataoka, Masae Torii, Chenfeng He, Nobuko Kawaguchi-Sakita, Masahiro Kawashima, Masahiro Takada, Eiji Suzuki, et al. The long-lasting anti-tumor activity of cisplatin affecting the sustainable systemic immune alteration may improve distant-disease free survival of triple-negative breast cancer in patients with a substantial residual tumor following preoperative chemotherapy: A retrospective analysis with translational research. JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 15
A pilot study of the use of positron emission tomography to evaluate early oestrogen receptor changes in patients with advanced and/or relapsed breast cancer administered endocrine therapy and CDK4/6 inhibitor combination therapy
(36th Annual Congress of the European Association of Nuclear Medicine 2023)
Updated survival outcomes of the POTENT trial of adjuvant S-1 and endocrine therapy in ER+/HER2- EBC
(第31回日本乳癌学会学術集会 2023)
SIGNIFICANCE OF COMPREHENSIVE GERIATRIC ASSESSMENT IN CHEMOTHERAPY FOR OLDER PATIENTS A SYSTEMATIC REVIEW AND JAPANESE GUIDELINE RECOMMENDATIONS
(MASCC/JASCC/ISOO Annual meeting 2023)
日本がん支持療法研究グループ
, 米国財団法人野口医学研究所
, Multinational Association of Supportive Care in Cancer
, 日本がんサポーティブケア学会
, 京都乳癌研究ネットワーク
, 日本臨床薬理学会
, 日本緩和医療学会
, 日本癌治療学会
, 日本乳癌学会
, 日本臨床腫瘍学会
, American College of Physicians
, 日本内科学会
, American Society of Clinical Oncology
, 東京海上日動メディカルサービス Nプログラム
, 腫瘍内科医会
, Japan Breast Cancer Research Group
, Japan Breast Cancer Research Group
